Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Regulatory Filings
2026-06-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-06-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-06-02 Korean
기업지배구조보고서공시
Governance Information Classification · 90% confidence The document is a detailed corporate governance report (“기업지배구조보고서”) covering governance structure, policies, board composition, shareholder meeting procedures, and compliance with governance principles for the 2025 fiscal year. It is neither an announcement of a report nor an annual financial report, but a standalone governance disclosure document. This matches the definition of Governance Information (Code: CGR).
2026-06-01 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Korean for Quarterly Report) covering the period from January 1, 2026 to March 31, 2026 (the 49th term). It contains detailed financial statements, tables on revenue, production, capital changes, share holdings, and other substantive interim-period data. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 75% confidence The document is a voluntary regulatory disclosure (“자율공시”) by Hana Pharm presenting its corporate value enhancement plan. It is not an annual or interim financial report, executive compensation disclosure, dividend notice, or management change announcement, nor does it convey a financing transaction. It is a standalone corporate plan filing that does not fit into any other specific category. Therefore, the correct classification is the general Regulatory Filings category (RNS).
2026-04-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.